What You Should Know:
- Centivax, a biotech company developing durable, universal vaccines, today announced the close of a $45 million Series A led by Steve Jurvetson’s Future Ventures, with participation from NFX, BOLD Capital, Base4, Kendall Capital Partners, Amplify Bio, and existing investors.
- The new funding will advance Centivax’s lead universal flu vaccine candidate through CMC development and into a Phase I trial within eight months.
Centivax Accelerates Universal Vaccine
Read More
Life Sciences | News, Analysis, Insights - HIT Consultant
Certara Expands Partnership with Merck to Streamline Drug Development Data Standards
What You Should Know:
- Certara, a global leader in model-informed drug development, today announced an expanded collaboration with Merck, known as MSD outside of the United States and Canada.
- The strategic agreement will see Merck increase its use of the Certara Pinnacle 21 software platform to include a metadata repository and data standards workflow management. This builds upon Merck’s existing technology collaboration with Certara aimed at aiding regulatory
Read More
The Future of MedTech Compliance: Why Dynamic Data is Transforming QARA
Technology advances are driving today's rapidly evolving medical device landscape and, as a result, traditional Quality Assurance and Regulatory Affairs (QARA) approaches are becoming increasingly obsolete. The industry is at a critical inflection point where static data management can no longer keep pace with the volume and complexity of global regulatory changes. This transformation is fermenting a fundamental shift toward dynamic data systems powered by artificial intelligence.
The
Read More
Catalio Capital Management Closes $400M+ Fund IV to Fuel Breakthrough Biomedical Innovation
What You Should Know:
- Catalio Capital Management, LP (“Catalio”), a healthcare investment firm, today announced the successful close of its fourth venture fund, Catalio Nexus Fund IV (“Fund IV”), with over $400M in commitments across the Fund and its related co-investment vehicles.
- Launched in 2020 by Co-Founders George Petrocheilos and Dr. Jacob Vogelstein, Catalio currently manages $2B in assets across its private equity, private credit, and public equities
Read More
LogicFlo AI Secures $2.7M to Optimize Life Sciences with AI Agent Workforce
What You Should Know:
- LogicFlo AI, a pioneering Boston-based startup, today announced it has secured $2.7M in seed funding led by Lightspeed with participation from healthcare and enterprise AI investors.
- The investment will accelerate the deployment of its intelligent agent platform across the pharmaceutical, biotech, and medtech industries. LogicFlo AI aims to free life sciences experts from tedious "busywork" by providing them with AI collaborators for high-stakes,
Read More
Verily and Vanderbilt Extend Partnership to Power NIH’s All of Us Researcher Workbench
What You Should Know:
- Verily and Vanderbilt University Medical Center (VUMC) today announced the continuation of their crucial partnership, ensuring the ongoing success and enhancement of the National Institutes of Health (NIH) All of Us Research Program’s Researcher Workbench platform.
- The extended 5-year collaboration reinforces Verily's role as a key technology partner, providing secure, cloud-based access to invaluable biomedical data for researchers worldwide.
A
Read More
Causaly Launches AI-powered Competitive Intelligence App for Early-Stage Drug Discovery
What You Should Know:
- Causaly today announced Pipeline Graph, giving pharma research and development teams a more effective and efficient way to do competitive intelligence earlier in drug discovery.
- The AI-powered application lets scientists proactively find and access competitive insights while they evaluate viable drug targets, helping them make confident pipeline decisions faster before investing in costly drug development programs.
Causaly Launches Pipeline Graph to Integrate
Read More
AI in Pharmacovigilance: Why True Transformation Starts with Workflow Re-Engineering
There is no doubt that the introduction of artificial intelligence into the field of pharmacovigilance is making waves. According to a 2025 McKinsey survey of leaders in the pharma and MedTech industries, 32% of life sciences organizations are spending $5 million or more on generative AI budgets. Specifically, there was a 7% increase in the number of respondents expecting to allocate more than $10 million in generative AI budgets, and a 5% increase in respondents planning to spend between $5 and
Read More
The Next Phase of RWE: Why Integration Matters More Than Data Collection
Real-world evidence (RWE) has become central to evaluating therapies, medical products, and health interventions—providing insight into how they perform outside controlled clinical trials. As healthcare systems seek more timely, representative, and cost-effective approaches to evidence generation, real-world data (RWD) is increasingly used to inform regulatory decisions, guide clinical practice, and shape health policy.
As RWE gains traction, fundamental questions remain: How do we ensure
Read More
Caris Life Sciences Announces Pricing of Initial Public Offering
What You Should Know:
- Caris Life Sciences® (Caris), an AI TechBio company and pioneer in precision medicine, today announced the pricing of its initial public offering (IPO) of 23,529,412 shares of its common stock at a public offering price of $21.00 per share.
- The shares are expected to begin trading on the Nasdaq Global Select Market on June 18, 2025, under the ticker symbol “CAI.” The offering is expected to close on June 20, 2025, subject to customary closing
Read More
